Rotavirus
is a common type of virus that infects the intestine in human body. Easily
spread among infants and children, this virus is the most communal cause of
diarrhea across the globe, which has caused the death of approximately 500,000
children annually.In few cases even adults become infected of the virus, however
the illness is usually mild.
It is
observed that almost 95% of the respective virus happens in young children who
belong to low-income countries including Asia and Africa. This can be due to
the fact that lifesaving care is limited or not available at all in
underdeveloped countries.
In
order to prevent oneself, vaccination is the best way that is highly contagious
and easily responds to traditional diarrhea prevention methods.Since the year 2006,
vaccination for rotavirus infection has been available in the market for public.
The Vaccines
In
order to fight against rotavirus, a new vaccine by the name of ROTAVAC® is
awaiting licensure in India. If approved, this vaccine could transform the rotavirus children prevention motive
including adults cure. The vaccination will be as cheap as $1 per dose to protect
children. PATH, a cross-sector partnership led by Indian Government was
involved in the development of vaccine.
It provided technical support on various basic as well as critical clinical
trials and manufacturing issues. PATH is also in close coordination with the manufacturers
in China, India, and the United States to safeguard other rotavirus vaccine
candidates, out of whom some are under clinical trials.
Apart
from this, there are two existing rotavirus vaccines available across the
geographies and are highly safe to use. These vaccinations are so effective
that countries have seen drastic reductions in severe and fatal diarrhea.
The Future
After
receiving license for ROTAVAC in India, the owners can submit the vaccine to
World Health Organization for prequalification. This will be a significant step
in targeting effected children all over the countries with the pocket-friendly vaccine.